AU3185671A - Creation of Inventions and Patents with Artificial Intelligence

AU3185671A – Orally effective analgetic composition
– Google Patents

AU3185671A – Orally effective analgetic composition
– Google Patents
Orally effective analgetic composition

Info

Publication number
AU3185671A

AU3185671A
AU31856/71A
AU3185671A
AU3185671A
AU 3185671 A
AU3185671 A
AU 3185671A
AU 31856/71 A
AU31856/71 A
AU 31856/71A
AU 3185671 A
AU3185671 A
AU 3185671A
AU 3185671 A
AU3185671 A
AU 3185671A
Authority
AU
Australia
Prior art keywords
orally effective
analgetic composition
effective analgetic
composition
orally
Prior art date
1970-08-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
AU31856/71A
Other versions

AU463074B2
(en

Inventor
JACOB PACHTER and MAXWELL GORDON IRWIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Co

Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1970-08-03
Filing date
1971-07-30
Publication date
1973-02-01

1971-07-30
Application filed by Bristol Myers Co
filed
Critical
Bristol Myers Co

1973-02-01
Publication of AU3185671A
publication
Critical
patent/AU3185671A/en

1975-07-17
Application granted
granted
Critical

1975-07-17
Publication of AU463074B2
publication
Critical
patent/AU463074B2/en

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/33—Heterocyclic compounds

A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/33—Heterocyclic compounds

A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

A61K31/47—Quinolines; Isoquinolines

A61K31/485—Morphinan derivatives, e.g. morphine, codeine

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/33—Heterocyclic compounds

A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

AU31856/71A
1970-08-03
1971-07-30
Orally effective analgetic composition

Expired

AU463074B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US6062170A

1970-08-03
1970-08-03

USUS60621

1970-08-03

Publications (2)

Publication Number
Publication Date

AU3185671A
true

AU3185671A
(en)

1973-02-01

AU463074B2

AU463074B2
(en)

1975-07-17

Family
ID=22030682
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU31856/71A
Expired

AU463074B2
(en)

1970-08-03
1971-07-30
Orally effective analgetic composition

Country Status (9)

Country
Link

US
(1)

US3773955A
(en)

AU
(1)

AU463074B2
(en)

BE
(1)

BE770625A
(en)

DE
(1)

DE2138593A1
(en)

DK
(1)

DK133035B
(en)

FR
(1)

FR2101191B1
(en)

GB
(1)

GB1353815A
(en)

NL
(1)

NL7109388A
(en)

ZA
(1)

ZA714683B
(en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3885027A
(en)

1971-04-12
1975-05-20
West Laboratories Inc
Orally administered drug composition for therapy in the treatment of narcotic drug addiction

US3896226A
(en)

1971-11-26
1975-07-22
Lewinstein Evalina
6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist

US3906100A
(en)

1973-05-24
1975-09-16
Miles Lab
N-benzyl-N-{8 2-phenyl-2-(4-phenyl-1-piperidyl)-ethyl{9 -propionamide para-chlorobenzene sulfonate

US4048316A
(en)

1974-03-04
1977-09-13
Penn Nathar W
Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning

US4126684A
(en)

1976-02-11
1978-11-21
Ciba-Geigy Corporation
4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse

US4457933A
(en)

1980-01-24
1984-07-03
Bristol-Myers Company
Prevention of analgesic abuse

JPS56128715A
(en)

1980-03-06
1981-10-08
Bristol Myers Co
Analgesic abuse prevention

US4366159A
(en)

1981-09-08
1982-12-28
Michael Richard Magruder
Nalbuphine-narcotic analgesic composition and method of producing analgesia

DE3216327C1
(en)

1982-05-03
1983-05-19
Siempelkamp Gießerei GmbH & Co, 4150 Krefeld
Production of thick-walled shielded transport and storage containers of spherulitic cast iron

JPS59501712A
(en)

1982-08-25
1984-10-11
バ−ンステイン，ジヨエル　イ−．

Method for treating itch and composition therefor

GB8332556D0
(en)

1983-12-06
1984-01-11
Reckitt & Colmann Prod Ltd
Analgesic compositions

US4888346A
(en)

1986-10-07
1989-12-19
Bernard Bihari
Method for the treatment of persons infected with HTLV-III (AIDS) virus

US5236714A
(en)

1988-11-01
1993-08-17
Alza Corporation
Abusable substance dosage form having reduced abuse potential

KR100243956B1
(en)

1991-09-06
2000-03-02
랄프 알. 팔로
Composition comprising a tramadol material and actaminophen for the treatment of pain

US7027859B1
(en)

1994-09-26
2006-04-11
Alza Corporation
Electrotransport delivery device having improved safety and reduced abuse potential

US5587381A
(en)

1995-03-27
1996-12-24
Sinclair; John D.
Method for terminating methadone maintenance through extinction of the opiate-taking responses

US6375957B1
(en)

1997-12-22
2002-04-23
Euro-Celtique, S.A.
Opioid agonist/opioid antagonist/acetaminophen combinations

DK1685839T3
(en)

1997-12-22
2013-06-24
Euro Celtique Sa

Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist

UA53774C2
(en)

1997-12-22
2003-02-17
Еро-Селтік, С.А.
Method of reducing abuse potential of an oral dosage form of opioid analgesic

CA2380524A1
(en)

1999-08-25
2001-03-01
Barrett R. Cooper
Compositions and methods for treating opiate intolerance

CN101703777B
(en)

2000-02-08
2012-11-28
欧罗赛铁克股份有限公司
Tamper-resistant oral opioid agonist formulations

US6716449B2
(en)

2000-02-08
2004-04-06
Euro-Celtique S.A.
Controlled-release compositions containing opioid agonist and antagonist

ATE493130T1
(en)

2001-05-11
2011-01-15
Endo Pharmaceuticals Inc

MEDICINAL FORM CONTAINING OPIOID AGAINST ABUSE

JP2005515960A
(en)

2001-05-11
2005-06-02
エンドーファーマシューティカルズ，インコーポレイティド

Abuse-resistant opioid dosage form

US7766013B2
(en)

2001-06-05
2010-08-03
Alexza Pharmaceuticals, Inc.
Aerosol generating method and device

WO2003002100A1
(en)

2001-06-26
2003-01-09
Farrell John J
Tamper-proof narcotic delivery system

AU2002316738B2
(en)

2001-07-18
2009-01-08
Euro-Celtique S.A.
Pharmaceutical combinations of oxycodone and naloxone

JP4504013B2
(en)

2001-08-06
2010-07-14
ユーロ−セルティークエス．エイ．

Opioid agonist formulations having releasable and sequestered antagonists

US20030157168A1
(en)

2001-08-06
2003-08-21
Christopher Breder
Sequestered antagonist formulations

US20030044458A1
(en)

2001-08-06
2003-03-06
Curtis Wright
Oral dosage form comprising a therapeutic agent and an adverse-effect agent

US20030068276A1
(en)

2001-09-17
2003-04-10
Lyn Hughes
Dosage forms

US20040126428A1
(en)

2001-11-02
2004-07-01
Lyn Hughes
Pharmaceutical formulation including a resinate and an aversive agent

TWI334779B
(en)

2002-04-05
2010-12-21
Euro Celtique Sa
Pharmaceutical preparation containing oxycodone and naloxone

US20030199439A1
(en)

2002-04-22
2003-10-23
Simon David Lew
Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics

KR20050050615A
(en)

2002-04-23
2005-05-31
알자 코포레이션
Transdermal analgesic systems with reduced abuse potential

US8557291B2
(en)

2002-07-05
2013-10-15
Collegium Pharmaceutical, Inc.
Abuse-deterrent pharmaceutical compositions of opioids and other drugs

US10004729B2
(en)

2002-07-05
2018-06-26
Collegium Pharmaceutical, Inc.
Tamper-resistant pharmaceutical compositions of opioids and other drugs

JP4694207B2
(en)

2002-07-05
2011-06-08
コルジウムファーマシューティカル，インコーポレイテッド

Abuse deterrent pharmaceutical compositions for opioids and other drugs

US8840928B2
(en)

2002-07-05
2014-09-23
Collegium Pharmaceutical, Inc.
Tamper-resistant pharmaceutical compositions of opioids and other drugs

US7815934B2
(en)

2002-09-20
2010-10-19
Alpharma Pharmaceuticals, Llc
Sequestering subunit and related compositions and methods

US20040202717A1
(en)

2003-04-08
2004-10-14
Mehta Atul M.
Abuse-resistant oral dosage forms and method of use thereof

CA2519556C
(en)

2003-04-21
2011-01-18
Benjamin Oshlack
Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same

MY135852A
(en)

2003-04-21
2008-07-31
Euro Celtique Sa
Pharmaceutical products

US7182955B2
(en)

2003-04-30
2007-02-27
3M Innovative Properties Company
Abuse-resistant transdermal dosage form

ME00276B
(en)

2003-04-30
2011-05-10
Purdue Pharma Lp
Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer

US8790689B2
(en)

2003-04-30
2014-07-29
Purdue Pharma L.P.
Tamper resistant transdermal dosage form

US20040219195A1
(en)

2003-04-30
2004-11-04
3M Innovative Properties Company
Abuse-resistant transdermal dosage form

CA2529984C
(en)

2003-06-26
2012-09-25
Isa Odidi
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors

KR20060120678A
(en)

2003-10-30
2006-11-27
알자 코포레이션
Transdermal analgesic systems having reduced abuse potential

JP4917893B2
(en)

2003-12-09
2012-04-18
ユーロ−セルティークエス．エイ．

Unauthorized use prevention coextrusion agent type containing agonist and adverse agent, and method for producing the same

US8883204B2
(en)

2003-12-09
2014-11-11
Purdue Pharma L.P.
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same

CA2551127A1
(en)

2003-12-15
2005-07-07
Alexza Pharmaceuticals, Inc.
Treatment of breakthrough pain by drug aerosol inhalation

US20050165038A1
(en)

2004-01-22
2005-07-28
Maxwell Gordon
Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects

ATE419836T1
(en)

2004-03-30
2009-01-15
Euro Celtique Sa

TAMPER-PROOF DOSAGE FORM COMPRISING AN ADSORBENT AND AN ADVERSE AGENT

US7540286B2
(en)

2004-06-03
2009-06-02
Alexza Pharmaceuticals, Inc.
Multiple dose condensation aerosol devices and methods of forming condensation aerosols

EP1604667A1
(en)

2004-06-08
2005-12-14
Euro-Celtique S.A.
Opioids for the treatment of the restless leg syndrome

EP1604666A1
(en)

2004-06-08
2005-12-14
Euro-Celtique S.A.
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)

CA2569958C
(en)

2004-06-12
2016-03-22
Jane C. Hirsh
Abuse-deterrent drug formulations

US8394409B2
(en)

2004-07-01
2013-03-12
Intellipharmaceutics Corp.
Controlled extended drug release technology

KR20070053267A
(en)

2004-08-20
2007-05-23
쓰리엠 이노베이티브 프로퍼티즈 컴파니
Transdermal drug delivery device with translucent protective film

US10624858B2
(en)

2004-08-23
2020-04-21
Intellipharmaceutics Corp
Controlled release composition using transition coating, and method of preparing same

JP5704789B2
(en)

2005-01-28
2015-04-22
ユーロ−セルティークエス．エイ．

Alcohol resistant dosage form

TW200640526A
(en)

2005-02-24
2006-12-01
Alza Corp
Transdermal electrotransport drug delivery systems with reduced abuse potential

EP1702558A1
(en)

2005-02-28
2006-09-20
Euro-Celtique S.A.
Method and device for the assessment of bowel function

EP1695700A1
(en)

2005-02-28
2006-08-30
Euro-Celtique S.A.
Dosage form containing oxycodone and naloxone

EP1895995A2
(en)

2005-05-13
2008-03-12
Alza Corporation
Multilayer drug system for the delivery of galantamine

WO2006133103A2
(en)

2005-06-03
2006-12-14
Trans-Dermal Patents Company, Llc
Reservoir for delivery of agents

US20090143761A1
(en)

2005-06-03
2009-06-04
Transdermal Patents Company, Llc
Agent delivery system and uses of same

WO2007087452A2
(en)

2006-01-27
2007-08-02
Theraquest Biosciences, Llc
Abuse resistant and extended release formulations and method of use thereof

US9125833B2
(en)

2005-11-02
2015-09-08
Relmada Therapeutics, Inc.
Multimodal abuse resistant and extended release opioid formulations

WO2007056142A2
(en)

2005-11-02
2007-05-18
Theraquest Biosciences, Llc
Methods of preventing the serotonin syndrome and compositions for use therefor

US8329744B2
(en)

2005-11-02
2012-12-11
Relmada Therapeutics, Inc.
Methods of preventing the serotonin syndrome and compositions for use thereof

US10064828B1
(en)

2005-12-23
2018-09-04
Intellipharmaceutics Corp.
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems

EP1810670A1
(en)

2006-01-19
2007-07-25
Holger Lars Hermann
Combination of Polamidone and Naloxone for the treatment of drug addiction

ZA200807571B
(en)

2006-03-01
2009-08-26
Ethypharm Sa
Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion

CA2648280C
(en)

2006-04-03
2014-03-11
Isa Odidi
Controlled release delivery device comprising an organosol coat

US10960077B2
(en)

2006-05-12
2021-03-30
Intellipharmaceutics Corp.
Abuse and alcohol resistant drug composition

US20070278289A1
(en)

2006-05-31
2007-12-06
Toshiba Tec Kabushiki Kaisha
Payment adjusting apparatus and program therefor

PL2034975T3
(en)

2006-06-19
2012-09-28
Alpharma Pharmaceuticals Llc
Pharmaceutical compositions

EP1897543A1
(en)

2006-08-30
2008-03-12
Euro-Celtique S.A.
Buprenorphine- wafer for drug substitution therapy

ES2594867T3
(en)

2007-03-09
2016-12-23
Alexza Pharmaceuticals, Inc.

Heating unit for use in a drug delivery device

US7748244B2
(en)

2007-09-14
2010-07-06
Schlage Lock Company
Deadbolt lock assembly

WO2009059050A2
(en)

2007-10-30
2009-05-07
The Regents Of The University Of Colorado
Tlr modulators and methods for using the same

US20110251229A1
(en)

2007-10-30
2011-10-13
The Regents Of The University Of Colorado
(+)-opioids and methods of use

US8623418B2
(en)

2007-12-17
2014-01-07
Alpharma Pharmaceuticals Llc
Pharmaceutical composition

JP5886632B2
(en)

2009-03-10
2016-03-16
ユーロ−セルティークエス．エイ．

Immediate release pharmaceutical composition comprising oxycodone and naloxone

US10668060B2
(en)

2009-12-10
2020-06-02
Collegium Pharmaceutical, Inc.
Tamper-resistant pharmaceutical compositions of opioids and other drugs

AU2012219322A1
(en)

2011-02-17
2013-05-09
QRxPharma Ltd.
Technology for preventing abuse of solid dosage forms

CA2918004C
(en)

2013-07-23
2018-11-20
Euro-Celtique S.A.
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

DK201600098Y3
(en)

2015-09-03
2017-02-10
Acino Pharma Ag
Limiting deallylation of naloxone during storage of naloxonholdig depot

US9737530B1
(en)

2016-06-23
2017-08-22
Collegium Pharmaceutical, Inc.
Process of making stable abuse-deterrent oral formulations

US10532385B2
(en)

2016-06-29
2020-01-14
Disposerx, Inc.
Disposal of medicaments

1970

1970-08-03
US
US00060621A
patent/US3773955A/en
not_active
Expired – Lifetime

1971

1971-07-07
NL
NL7109388A
patent/NL7109388A/xx
unknown

1971-07-08
GB
GB3207771A
patent/GB1353815A/en
not_active
Expired

1971-07-15
ZA
ZA714683A
patent/ZA714683B/en
unknown

1971-07-28
BE
BE770625A
patent/BE770625A/en
unknown

1971-07-30
AU
AU31856/71A
patent/AU463074B2/en
not_active
Expired

1971-08-02
DE
DE19712138593
patent/DE2138593A1/en
active
Pending

1971-08-02
FR
FR7128227A
patent/FR2101191B1/fr
not_active
Expired

1971-08-03
DK
DK378571AA
patent/DK133035B/en
unknown

Also Published As

Publication number
Publication date

DE2138593A1
(en)

1972-03-30

FR2101191B1
(en)

1975-02-07

US3773955A
(en)

1973-11-20

GB1353815A
(en)

1974-05-22

FR2101191A1
(en)

1972-03-31

AU463074B2
(en)

1975-07-17

BE770625A
(en)

1972-01-28

DK133035B
(en)

1976-03-15

NL7109388A
(en)

1972-02-07

ZA714683B
(en)

1972-04-26

Información de contacto